A top an­a­lyst sees 'in­flec­tion point' in the oth­er big vac­cine race tak­ing phar­ma by storm

Be­neath the Covid-19 vac­cine race, there’s an­oth­er vac­cine race in full swing, with bil­lions on the line and many of the same lead­ing play­ers edg­ing for first: the race for an RSV vac­cine.

Al­though the sea­son­al in­fec­tion can be dead­ly in young chil­dren and the el­der­ly, sci­en­tists have failed for decades to come up with a vac­cine. An ear­ly tri­al in the 1960s end­ed in dis­as­ter, af­ter it ap­peared the vac­cine ac­tu­al­ly helped the virus in­fect cells. Re­cent ad­vance­ments, though, have re­newed in­ter­est in what could be a $10 bil­lion mar­ket, bring­ing in ef­forts from ma­jor de­vel­op­ers, in­clud­ing Pfiz­er, Mod­er­na, J&J, Mer­ck, Sanofi and Glax­o­SmithK­line.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER